<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699994</url>
  </required_header>
  <id_info>
    <org_study_id>N20190007</org_study_id>
    <nct_id>NCT04699994</nct_id>
  </id_info>
  <brief_title>Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel</brief_title>
  <official_title>Multicenter Phase II Trial to Evaluate the Safety and Efficacy of FLOT Therapy for Resectable Esophageal Squamous Cell Carcinoma (Preoperative FLOT PII)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keio University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current multicenter prospective phase II study aims to evaluate the safety and efficacy&#xD;
      of preoperative FLOT therapy for esophageal squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological response rate (Grade 2 or 3 in Japanese Classification of Esophageal Cancer, 11th Edition)</measure>
    <time_frame>2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological complete response rate</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment completion rate</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Curative resection rate</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>4.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of adverse event during FLOT</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative complication rate</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late phase complication rate</measure>
    <time_frame>4.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of severe adverse event</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of all adverse event</measure>
    <time_frame>4.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>FLOT therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLOT therapy</intervention_name>
    <description>Preoperative FLOT therapy</description>
    <arm_group_label>FLOT therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically diagnosed as esophageal squamous cell carcinoma (squamous,&#xD;
             adenosquamous, basaloid)&#xD;
&#xD;
          2. Primary tumor is located mainly in the thoracic esophagus&#xD;
&#xD;
          3. cT1N1-3M0-1 (only supraclavicular LN metastasis is included as M1), cT2-3N0-3M0-1&#xD;
             (only supraclavicular LN metastasis is included as M1)&#xD;
&#xD;
          4. Twenty years old or older as of registration&#xD;
&#xD;
          5. Performance status (PS) 0 or 1&#xD;
&#xD;
          6. Patients have target lesions&#xD;
&#xD;
          7. No previous history of esophageal cancer except for the followings&#xD;
&#xD;
        1) pT1a-LPM (M2) or deeper following EMR/ESD 2) pT1a-MM (M3) with vascular invasion&#xD;
        following EMR/ ESD 8. No previous history of chemotherapy/radiotherapy/endocrine therapy&#xD;
        except for hormone therapy for prostate cancer after 5 years interval 9. Patients who meet&#xD;
        the following criteria&#xD;
&#xD;
          1. Neutrophil &gt; 1,500 /mm3&#xD;
&#xD;
          2. Platelet &gt; 10.0x10^4 /mm3&#xD;
&#xD;
          3. Hb ≧9.0 g/dL&#xD;
&#xD;
          4. Total bilirubin ≦ 1.5 mg/dL&#xD;
&#xD;
          5. AST ≦ 100 IU/L&#xD;
&#xD;
          6. ALT ≦ 100 IU/L&#xD;
&#xD;
          7. SpO2 ≧ 95 %&#xD;
&#xD;
          8. Creatinine clearance ≧ 50 mL/min 10. Patients who can undergo esophagectomy 11. Agree&#xD;
             with the participation to the current study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who received any treatment for cancer within 3 years&#xD;
&#xD;
          2. Patients who have active infectious diseases&#xD;
&#xD;
          3. HBs Ag positive or HIV Ab positive&#xD;
&#xD;
          4. Pregnant or breast feeding&#xD;
&#xD;
          5. Patients with psychological disorder&#xD;
&#xD;
          6. On systemic steroid therapy&#xD;
&#xD;
          7. Require flucytocine, phenytoin, warfarin&#xD;
&#xD;
          8. Allergic to iodine&#xD;
&#xD;
          9. Allergic to DTX, LOHP, polisorbate 80&#xD;
&#xD;
         10. Uncontrollable diabetes&#xD;
&#xD;
         11. Severe COPD or lung fibrosis&#xD;
&#xD;
         12. Severe hypertension&#xD;
&#xD;
         13. Unstable angina&#xD;
&#xD;
         14. Patients whom investigators evaluate as ineligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Satoru Matsuda</last_name>
    <phone>+81333531211</phone>
    <email>s.matsuda.a8@keio.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>1608582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satoru Matsuda</last_name>
      <phone>+81333531211</phone>
      <email>s.matsuda.a8@keio.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Keio University</investigator_affiliation>
    <investigator_full_name>Hirofumi Kawakubo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

